Raiffeisen Bank International AG Makes New $815,000 Investment in PROCEPT BioRobotics Corporation $PRCT

Raiffeisen Bank International AG acquired a new stake in PROCEPT BioRobotics Corporation (NASDAQ:PRCT) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 14,000 shares of the company’s stock, valued at approximately $815,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Alliancebernstein L.P. increased its position in shares of PROCEPT BioRobotics by 22.3% during the 1st quarter. Alliancebernstein L.P. now owns 2,143,693 shares of the company’s stock valued at $124,892,000 after purchasing an additional 391,215 shares during the last quarter. T. Rowe Price Investment Management Inc. lifted its position in PROCEPT BioRobotics by 43.6% in the first quarter. T. Rowe Price Investment Management Inc. now owns 1,415,403 shares of the company’s stock worth $82,462,000 after buying an additional 429,461 shares during the last quarter. Geode Capital Management LLC boosted its stake in PROCEPT BioRobotics by 9.7% during the second quarter. Geode Capital Management LLC now owns 1,298,894 shares of the company’s stock worth $74,826,000 after buying an additional 115,229 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in PROCEPT BioRobotics by 47.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,055,762 shares of the company’s stock worth $61,510,000 after buying an additional 341,906 shares during the period. Finally, Westfield Capital Management Co. LP increased its position in PROCEPT BioRobotics by 43.2% during the first quarter. Westfield Capital Management Co. LP now owns 748,557 shares of the company’s stock valued at $43,611,000 after acquiring an additional 225,894 shares during the last quarter. Hedge funds and other institutional investors own 89.46% of the company’s stock.

Analyst Ratings Changes

PRCT has been the subject of several analyst reports. BTIG Research restated a “neutral” rating on shares of PROCEPT BioRobotics in a report on Tuesday, September 16th. Piper Sandler reissued an “overweight” rating and issued a $50.00 price objective (down from $55.00) on shares of PROCEPT BioRobotics in a research report on Wednesday, November 5th. Wall Street Zen downgraded shares of PROCEPT BioRobotics from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Weiss Ratings restated a “sell (e+)” rating on shares of PROCEPT BioRobotics in a research report on Wednesday, October 8th. Finally, Truist Financial reduced their price target on PROCEPT BioRobotics from $64.00 to $50.00 and set a “buy” rating on the stock in a report on Wednesday, October 15th. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, PROCEPT BioRobotics has a consensus rating of “Moderate Buy” and an average target price of $59.78.

PROCEPT BioRobotics Trading Down 2.3%

PRCT stock opened at $28.40 on Wednesday. PROCEPT BioRobotics Corporation has a 12 month low of $28.28 and a 12 month high of $100.89. The firm’s 50-day moving average is $34.74 and its 200 day moving average is $46.39. The company has a market capitalization of $1.59 billion, a PE ratio of -18.56 and a beta of 0.98. The company has a debt-to-equity ratio of 0.14, a current ratio of 8.44 and a quick ratio of 7.20.

PROCEPT BioRobotics (NASDAQ:PRCT) last issued its earnings results on Tuesday, November 4th. The company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.03. The business had revenue of $83.33 million for the quarter, compared to the consensus estimate of $80.78 million. PROCEPT BioRobotics had a negative net margin of 28.20% and a negative return on equity of 21.72%. The company’s revenue for the quarter was up 42.6% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.40) EPS. PROCEPT BioRobotics has set its FY 2026 guidance at EPS. FY 2025 guidance at EPS. On average, research analysts anticipate that PROCEPT BioRobotics Corporation will post -1.75 EPS for the current year.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).